Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)
NCT07086521Phase 1Recruiting
- Sponsor
- Restem
- Start
- Dec 2025
- Primary completion
- Sep 2029
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of umbilical cord lining stem cells in facioscapulohumeral muscular dystrophy (FSHD) (2 arms), sponsored by Restem. Primary endpoint: Adverse Events and Serious Adverse Events at 12 months. Started Dec 2025; status: recruiting.
02
Drugs
umbilical cord lining stem cells
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on NCT07086521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07086521.